Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernd Gerber

Showing results (101-110 of 173) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer StudyFrederick Klauschen, Stephan Wienert, Wolfgang D Schmitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast GroupGunter von Minckwitz, Günter Raab, Angelika Caputo, et al.
International Journal of Radiation Oncology, Biology, Physics|May 22, 2020
Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA TrialGuido Hildebrandt, Angrit Stachs, Bernd Gerber, et al.
Breast (Edinburgh, Scotland)|February 29, 2024
Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapyDavid Krug, Valentina Vladimirova, Michael Untch, et al.
Clinical Breast Cancer|November 12, 2002
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysisChristian Jackisch, Gunter von Minckwitz, Holger Eidtmann, et al.
Breast Cancer Research and Treatment|August 13, 2011
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapySibylle Loibl, Berit Maria Müller, Gunter von Minckwitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2015
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)Claus Hanusch, Andreas Schneeweiss, Sibylle Loibl, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2015
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapyFrederik Marmé, Bianca Lederer, Jens-Uwe Blohmer, et al.
Breast Cancer (Tokyo, Japan)|June 30, 2019
Fatal events during clinical trials: an evaluation of deaths during breast cancer studiesJenny Furlanetto, Gunter von Minckwitz, Bianca Lederer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2018
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)Michael Untch, Gunter von Minckwitz, Bernd Gerber, et al.
Pageof 18

Showing results (101-110 of 173) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer StudyFrederick Klauschen, Stephan Wienert, Wolfgang D Schmitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast GroupGunter von Minckwitz, Günter Raab, Angelika Caputo, et al.
International Journal of Radiation Oncology, Biology, Physics|May 22, 2020
Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA TrialGuido Hildebrandt, Angrit Stachs, Bernd Gerber, et al.
Breast (Edinburgh, Scotland)|February 29, 2024
Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapyDavid Krug, Valentina Vladimirova, Michael Untch, et al.
Clinical Breast Cancer|November 12, 2002
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysisChristian Jackisch, Gunter von Minckwitz, Holger Eidtmann, et al.
Breast Cancer Research and Treatment|August 13, 2011
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapySibylle Loibl, Berit Maria Müller, Gunter von Minckwitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2015
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)Claus Hanusch, Andreas Schneeweiss, Sibylle Loibl, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2015
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapyFrederik Marmé, Bianca Lederer, Jens-Uwe Blohmer, et al.
Breast Cancer (Tokyo, Japan)|June 30, 2019
Fatal events during clinical trials: an evaluation of deaths during breast cancer studiesJenny Furlanetto, Gunter von Minckwitz, Bianca Lederer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2018
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)Michael Untch, Gunter von Minckwitz, Bernd Gerber, et al.
Pageof 18